AI Science Tracker
EN

Imidacloprid contributes to bladder cancer progression: preliminary evidence based on network toxicology, machine learning and molecular docking.

Affiliation not stated in the reviewed material · 30 Oct 2025 · biology

Discovery

Imidacloprid contributes to bladder cancer progression: preliminary evidence based on network toxicology, machine learning and molecular docking.

Source check: Source checked. Not independent scientific confirmation.

Finding: Machine-learning analyses of imidacloprid-related and bladder-cancer expression data identified a five-gene prognostic signature (SREBF1, PRELP, TGFBI, TNFAIP2 and TACR3), evaluated in TCGA and two GEO cohorts. In bladder-cancer cell assays, imidacloprid exposure increased measured proliferation, migration and invasion; expression assays showed changes in four of the five genes, while TACR3 did not significantly change. The cell findings do not establish that imidacloprid causes bladder cancer in people or that the risk model improves patient outcomes.

Technology: Ten machine-learning algorithms and combinations analyzed CTD exposure-related genes and TCGA expression data; multivariable Cox analysis formed a five-gene risk score.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning models selected exposure-related expression features for prognosis; the separate cell experiments directly tested imidacloprid-associated cellular behavior.
Test and result
The prognostic signature was assessed in TCGA and external GSE13507 and GSE31684 cohorts. Cell assays measured proliferation, wound closure and invasion after exposure; RT-qPCR and western blot checked gene expression. Four genes changed in the reported assays; TACR3 did not significantly change.
Limitation / still unknown
The cohort analyses are retrospective and the cell assays are in vitro. Neither shows that the exposure causes bladder cancer in people, nor establishes prospective clinical utility of the prognostic model.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12577002/ · https://europepmc.org/article/MED/41168844

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse biology discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.